BioCryst Pharmaceuticals Inc (BCRX): Cost of Revenue
$19.07M
Year ended 2025-12-31
$20.93M
Trailing 12 months to 2026-06-30
+43.9%
3-year compound annual growth
+65.2%
5-year compound annual growth
+30.1%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.07M | +55.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $12.27M | +173.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $4.48M | -30.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $6.41M | -11.4% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $7.23M | +366.4% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $1.55M | -58.4% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $3.73M | n/a | 2022-02-28, From 2019-01-01 |
| No annual figure between 2017-12-31 and 2019-12-31. | |||
| 2017-12-31 | $1.14M | -50.3% | 2020-03-13, From 2017-01-01 |
| 2016-12-31 | $2.30M | +67.9% | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | $1.37M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $1.0K | n/a | 2017-02-27, From 2014-01-01 |
| No annual figure between 2010-12-31 and 2014-12-31. | |||
| 2010-12-31 | $86.0K | -98.1% | 2013-03-11, From 2010-01-01 |
| 2009-12-31 | $4.54M | n/a | 2012-03-06, From 2009-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $19.07M | +55.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $352.01M | -2.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $73.04M | -64.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $415.97M | -3.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $228.77M | +43.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $217.41M | +5.1% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $5.09M | +86.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $868.00M | -40.7% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $185.57M | +3.3% |
Compare BCRX, RGEN, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗